Related Experiment Video

Updated: Jun 25, 2026

Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
09:56

Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins

Published on: October 31, 2025

The promises and pitfalls of epigenetic therapies in solid tumours

Janet S Graham1, Stanley B Kaye2, Robert Brown1

  • 1Department of Oncology and Ovarian Cancer Action Centre, Imperial College, Hammersmith Campus, Du Cane Road, W12 0NN London, UK.

European Journal of Cancer (Oxford, England : 1990)
|February 13, 2009
PubMed

Insights

Epigenetic therapies can reverse gene silencing in cancer. While effective in blood cancers, their use in solid tumors faces challenges, requiring new trial designs and drug delivery methods.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic gene silencing, unlike mutations, is reversible by small molecules.
  • Epigenetic drugs are emerging as novel cancer therapies.
  • Current epigenetic therapies show promise in hematological malignancies but are less certain for solid tumors.

Purpose of the Study:

  • To review challenges in treating solid tumors with epigenetic therapies.
  • To discuss strategies for overcoming these obstacles.
  • To highlight the need for biomarker-driven trials and combination therapies.

Main Methods:

  • Literature review of epigenetic therapies in cancer treatment.
  • Analysis of challenges and potential solutions for solid tumor application.
  • Discussion of clinical trial design and drug development strategies.

Main Results:

  • Epigenetic therapies face significant hurdles in solid tumors.
  • Biomarker-driven trials focusing on optimal biological dose are needed.
  • Combination therapies, particularly with cytotoxics as chemosensitizers, show potential.
  • Improved tumor delivery, specificity, and reduced toxicity are crucial.

Conclusions:

  • Overcoming challenges in solid tumor treatment requires innovative approaches.
  • Pharmacodynamic biomarkers are essential for optimizing epigenetic drug dosing.
  • Enhanced drug delivery and reduced toxicity are key to realizing the potential of epigenetic therapies in solid tumors.

More Related Videos

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

Methylated DNA Immunoprecipitation21:24

Methylated DNA Immunoprecipitation

Published on: January 2, 2009

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...